Navigation Links
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
Date:8/25/2009

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, randomized study enrolled 50 subjects with SP-MS. A total of 36 subjects received PI-2301 once weekly for 8 weeks followed by an open label extension of an additional 4 weeks. The doses ranged from 1 to 60 mg. Safety at all doses, including potentially therapeutic doses, was established. The most frequent adverse events (AEs) were dose-dependent site reactions which were mild to moderate, transient, and resolved without specific therapy. Dose-dependent increases in serum levels of anti-inflammatory markers were consistent with PI-2301 exposure as measured using the Company's proprietary pharmacokinetic assay. The Company plans to continue developing this promising compound by initiating a Phase II study in multiple sclerosis patients later this year.

"PI-2301 has now shown safety and pharmacologic activity in two clinical studies, the first in healthy volunteers, and this second in patients with multiple sclerosis. As we look forward to the Phase II, we are excited about the observed pharmacologic effects of PI-2301 in patients suffering from secondary progressive MS," stated Thomas P. Mathers, President and CEO of Peptimmune.

Data from this Phase Ib study will be presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dr. Eric Zanelli will make a poster presentation titled "Clinical and biological results of a 12-week, double-blind, multiple ascending dose study evaluating the safety and tolerability of peptide copolymer PI-2301 in patients with the secondary progressive form of multiple sclerosis." The poster (P-422) will be presented within Topic 15 - Immunomodulation - 1 during the Poster Session I taking place on Thursday, September 10, 2009, between 2:30 and 5:00 p.m.

About PI-2301

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in autoimmune diseases such as multiple sclerosis. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis and other autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

In January 2009 Peptimmune granted Novartis (NYSE: NVS) an exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301.

About Multiple Sclerosis

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system attacks components of nerves. The effects of these immune-mediated attacks often progress to a chronic disabling disease, as communication between the brain and other parts of the body is disrupted.

About Peptimmune (www.peptimmune.com)

Peptimmune, Inc. is a privately held biotechnology company clinically focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP(TM) Technology to design peptide copolymers for the diagnosis and treatment of infectious diseases, autoimmune disorders, and the generation of novel antibodies. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peptimmune Presentations at Upcoming Events
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Peptimmune Announces First Close of Series D Private Financing
4. Cephalon Completes Acquisition of Arana Therapeutics
5. Cardinal Health Completes Biotech Acquisition
6. Beckman Coulter Completes Acquisition of Olympus Lab-Based Diagnostics Business
7. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
8. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
9. GlaxoSmithKline Completes Acquisition of Stiefel
10. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
11. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... for the Semiconductor, MEMS, and Microfluidics Industries, announces the new Model 800E front ... more often in automated production mask aligners. OAI has already received and ...
(Date:8/16/2017)... ... August 16, 2017 , ... Tunnell Consulting announced today that ... ISPE Annual Meeting and Expo , to be held October 29 through November ... is “Driving innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo ...
(Date:8/16/2017)... Philadelphia, PA (PRWEB) , ... August 16, 2017 , ... ... thought, they are much more closely connected than one might think. A Mesh ... Grizzly, will open at the University City Science Center’s Esther Klein Gallery (EKG) on ...
(Date:8/16/2017)... Mass. , Aug. 16, 2017  This year,s edition of the ... leader in life sciences workforce solutions, has made the list for the ... 5000 recognizes the nation,s fastest-growing private companies based on a set of ... 50, which includes the fastest-growing companies in the Bay State ... Inc. 5000 ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):